...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: "expert market"??

man o man donny must have something in the works eh?? The old "Expert Market" has been on fire - sike! Pathetic comes close but it's worse than that.

As mentioned in the AGM presentation, potential approval from the registration enabling studies (TNBC & CRPC) would be in 2023 and 2025.  (I'd be inclined to call it 2024 and 2026.)  So I don't expect the price to move until those are close to completion.  There's always the possibility of an earlier surprise, but I don't see a high probability of that.

 

 

Share
New Message
Please login to post a reply